Safety Alerts & Recalls
Mylan announced a voluntary recall of multiple injectable products due to the potential presence of visible foreign particulate matter.
The Food and Drug Administration (FDA) has issued warning letters to five manufacturers of dietary supplements due to the listing of R-beta-methylphenethylamine (also known as Beta-methylphenethylamine, βMePEA, or BMPEA) on the product label.
The Food and Drug Administration (FDA) has issued a Class 1 recall for the Ebola Virus One-Step Test Kits (LuSys Laboratories). This test kit has not been cleared or approved by the FDA for in vitro diagnostic detection of Ebola Virus infection.
The Food and Drug Administration (FDA) announced that Norpace CR (disopyramide phosphate; Pfizer) controlled-release 100mg is currently in shortage.
The Food and Drug Administration (FDA) announced that Bystolic (nebivolol; Forest Laboratories) 20mg is currently in shortage.
RB (formerly Reckitt Benckiser) announced a voluntary recall of certain lots of liquid bottles of over-the-counter (OTC) Mucinex Fast-Max due to mislabeling of drug facts.
The Food and Drug Administration (FDA) is warning consumers to not buy or use Extreme Diamond 3000, a product promoted and sold for sexual enhancement.
The FDA is warning pet owners, veterinarians, healthcare providers, and pharmacists that pets are at risk of illness and death when exposed to topical pain medications containing flurbiprofen.
The FDA is alerting healthcare providers and the public that counterfeit Botox (onabotulinumtoxin A; Allergan) has been found in the United States and may have been distributed to doctors' offices and clinics.
The FDA continues to warn consumers and caregivers not to use Eu Yan Sang (Hong Kong) Ltd.'s "Bo Ying compound" because of the possible lead poisoning risk associated with the product.
- Certain Food Combos Prevent Weight Gain, While Others Promote It
- The Vitamin D Debate: Conundrums and Complexities
- The Consequences of Ignoring the Complete Medication List
- Maple Syrup Boosts Antibiotic Effects in Proof-of-Concept Research
- New AHA/ACA/ASH Hypertension Guidelines: Lead Author Discusses Treatments and Controversies